ARQ 736 / Merck (MSD) - LARVOL DELTA

Dose escalation study of ARQ 736 in adult subjects with advanced solid tumors harboring BRAF and/or NRAS mutations (clinicaltrials.gov) - P1, N= 60 ->24; Sponsor: ArQule; Active, not recruiting -> Completed.

Enrollment change • Trial completion • Oncology